Patient and scientist led, research consulting firm that provides tailored services to advance end-to-end precision medicine solutions for rare diseases.
The development for Epidiolex (cannabidiol, CBD) for #Dravet and #LGS is spectacular: 3.5 years from IND to NDA, with three positive Phase 3 trials, each with over 100 patients. Much expectation at #AES2017. $GWPH has done an amazing job with this program.